Nutriband announces issuance of u.s. patent for transdermal abuse deterrent technology

Patent issuance expands u.s. patent portfolio for aversa™ transdermal abuse deterrent technology orlando, fl / accesswire / september 20, 2023 / nutriband inc. (nasdaq:ntrb)(nasdaq:ntrbw), a developer of transdermal pharmaceutical products, today announced that the united states patent and trademark office (uspto) has granted us patent no. 11,759,431 for nutriband's proprietary aversa™ abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches.
NTRB Ratings Summary
NTRB Quant Ranking